Last Updated : January 30, 2024
Details
FilesProject Status:
Completed
Project Line:
Health Technology Review
Project Sub Line:
Systematic Review
Project Number:
RE0051-000
Opioid use disorder (OUD) poses a serious public health issue in Canada. Buprenorphine formulations are important OUD treatment options but their comparative clinical effectiveness, safety, and cost-effectiveness are unclear. Previous reviews noted limited differences in clinical outcomes between different buprenorphine formulations but emphasized methodological issues and insufficient Canadian evidence. This report aims to analyze recent comparative evidence on buprenorphine formulations and assess their use in public drug plans across Canada. Clarifying these aspects will inform policy decisions on OUD treatment in Canada.
Files
Last Updated : January 30, 2024